LEO Pharma, an independent, research-based pharmaceutical company, has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for calcipotriene/betamethasone dipropionate aerosol foam 0,005 per cent/0,064 per cent for the treatment of psoriasis vulgaris.
The novel aerosol foam formulation of the fixed combination calcipotriene/betamethasone dipropionate has been developed with the aim of improving treatment for patients with psoriasis vulgaris1, the most common clinical form of psoriasis.
The regulatory submission in the US is based on studies of patients with psoriasis vulgaris. These include the phase 3a PSO-FAST study which evaluated efficacy, safety, itch relief and itch-related sleep loss across a four week period, and the phase 2 MUSE safety study.
Kim Kjøller, senior vice president, global development, commented, “Psoriasis is a chronic, debilitating disease. Patients with inadequately managed psoriasis can experience substantial burden of illness, with similar reductions in quality of life to those experienced by patients with diabetes or cancer.
With the regulatory submission announced recently, we are taking a step further in our mission towards reducing this burden by making calcipotriene/betamethasone dipropionate aerosol foam available for people living with psoriasis.”
Regulatory filings in Europe and other countries are planned during the course of 2015 and 2016.